OBJECTIVE: IGF1 and its most abundant binding protein, IGF-binding protein 3 (IGFBP3), have been implicated in fibrotic lung diseases and persistent acute respiratory distress syndrome (ARDS) due to profibrogenic and antiapoptotic activity. Whether circulating levels of IGF1 and IGFBP3 are altered in ARDS and whether they predict progression of and survival from ARDS remains unknown. This study aims to characterize the circulating levels of IGF1 and IGFBP3 in patients at risk for ARDS in relation to i) development of ARDS and ii) mortality among ARDS cases. DESIGN: In this case-cohort study, consecutive patients with risk factors for ARDS admitted to the intensive care unit were enrolled and followed prospectively for the development of ARDS. Cases were followed for all-cause mortality through day 60. Of the 2397 patients enrolled in the parent study, plasma samples were available in 531 (22%) patients (356 controls and 175 cases) from early in presentation. Total plasma IGF1 and IGFBP3 levels were measured. RESULTS: After adjusting for relevant clinical covariates including severity of illness, IGF1 and IGFBP3 levels were significantly lower in ARDS cases than in controls (odds ratio (OR), 0.58; P=0.006; OR, 0.57; P=0.0015 respectively). Among the ARDS cases, IGF1 and IGFBP3 levels were significantly lower in the 78 (45%) non-survivors (hazard ratio (HR), 0.70; P=0.024; HR, 0.69; P=0.021 respectively). CONCLUSIONS: Lower circulating levels of IGF1 and IGFBP3 were independently associated with ARDS case status. Furthermore, lower levels were associated with mortality among the ARDS cases. These data support the role of the IGF pathway in ARDS.
OBJECTIVE:IGF1 and its most abundant binding protein, IGF-binding protein 3 (IGFBP3), have been implicated in fibrotic lung diseases and persistent acute respiratory distress syndrome (ARDS) due to profibrogenic and antiapoptotic activity. Whether circulating levels of IGF1 and IGFBP3 are altered in ARDS and whether they predict progression of and survival from ARDS remains unknown. This study aims to characterize the circulating levels of IGF1 and IGFBP3 in patients at risk for ARDS in relation to i) development of ARDS and ii) mortality among ARDS cases. DESIGN: In this case-cohort study, consecutive patients with risk factors for ARDS admitted to the intensive care unit were enrolled and followed prospectively for the development of ARDS. Cases were followed for all-cause mortality through day 60. Of the 2397 patients enrolled in the parent study, plasma samples were available in 531 (22%) patients (356 controls and 175 cases) from early in presentation. Total plasma IGF1 and IGFBP3 levels were measured. RESULTS: After adjusting for relevant clinical covariates including severity of illness, IGF1 and IGFBP3 levels were significantly lower in ARDS cases than in controls (odds ratio (OR), 0.58; P=0.006; OR, 0.57; P=0.0015 respectively). Among the ARDS cases, IGF1 and IGFBP3 levels were significantly lower in the 78 (45%) non-survivors (hazard ratio (HR), 0.70; P=0.024; HR, 0.69; P=0.021 respectively). CONCLUSIONS: Lower circulating levels of IGF1 and IGFBP3 were independently associated with ARDS case status. Furthermore, lower levels were associated with mortality among the ARDS cases. These data support the role of the IGF pathway in ARDS.
Authors: L Pala; S Giannini; E Rosi; B Cresci; G Scano; S Mohan; R Duranti; C M Rotella Journal: J Endocrinol Invest Date: 2001-12 Impact factor: 4.256
Authors: Carolyn S P Lam; Ming-Huei Chen; Sean M Lacey; Qiong Yang; Lisa M Sullivan; Vanessa Xanthakis; Radwan Safa; Holly M Smith; Xuyang Peng; Douglas B Sawyer; Ramachandran S Vasan Journal: Arterioscler Thromb Vasc Biol Date: 2010-04-08 Impact factor: 8.311
Authors: R P Marshall; G Bellingan; S Webb; A Puddicombe; N Goldsack; R J McAnulty; G J Laurent Journal: Am J Respir Crit Care Med Date: 2000-11 Impact factor: 21.405
Authors: M A Spruit; R Gosselink; T Troosters; A Kasran; G Gayan-Ramirez; P Bogaerts; R Bouillon; M Decramer Journal: Thorax Date: 2003-09 Impact factor: 9.139
Authors: Peter M Krein; Peter J B Sabatini; William Tinmouth; Francis H Y Green; Brent W Winston Journal: Am J Respir Crit Care Med Date: 2003-01-01 Impact factor: 21.405
Authors: Amy M Ahasic; Paula Tejera; Yongyue Wei; Li Su; Christos S Mantzoros; Ednan K Bajwa; B Taylor Thompson; David C Christiani Journal: Crit Care Med Date: 2015-12 Impact factor: 7.598
Authors: Carmen Mikacenic; Brenda L Price; Susanna Harju-Baker; D Shane O'Mahony; Cassianne Robinson-Cohen; Frank Radella; William O Hahn; Ronit Katz; David C Christiani; Jonathan Himmelfarb; W Conrad Liles; Mark M Wurfel Journal: Am J Respir Crit Care Med Date: 2017-10-15 Impact factor: 21.405
Authors: Pavan Kumar Bhatraju; Leila R Zelnick; Ronit Katz; Carmen Mikacenic; Susanna Kosamo; William O Hahn; Victoria Dmyterko; Bryan Kestenbaum; David C Christiani; W Conrad Liles; Jonathan Himmelfarb; Mark M Wurfel Journal: Clin J Am Soc Nephrol Date: 2019-03-27 Impact factor: 8.237
Authors: Alan Leviton; Elizabeth N Allred; Raina N Fichorova; Deborah K VanderVeen; T Michael O'Shea; Karl Kuban; Olaf Dammann Journal: Am J Perinatol Date: 2019-01-27 Impact factor: 1.862
Authors: Xuesi Dong; Zhaozhong Zhu; Yongyue Wei; Debby Ngo; Ruyang Zhang; Mulong Du; Hui Huang; Lijuan Lin; Paula Tejera; Li Su; Feng Chen; Amy M Ahasic; B Taylor Thompson; Nuala J Meyer; David C Christiani Journal: Chest Date: 2020-11-12 Impact factor: 9.410
Authors: Sandeep Dhindsa; Nan Zhang; Michael J McPhaul; Zengru Wu; Amit K Ghoshal; Emma C Erlich; Kartik Mani; Gwendalyn J Randolph; John R Edwards; Philip A Mudd; Abhinav Diwan Journal: JAMA Netw Open Date: 2021-05-03
Authors: Inge Mannaerts; Ben Schroyen; Stefaan Verhulst; Leentje Van Lommel; Frans Schuit; Marc Nyssen; Leo A van Grunsven Journal: PLoS One Date: 2013-12-17 Impact factor: 3.240
Authors: Graciela Andonegui; Peter M Krein; Connie Mowat; Ronald Brisebois; Christopher Doig; Francis H Y Green; Caroline Léger; Brent W Winston Journal: Physiol Rep Date: 2014-11-03